Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Very low Apgar score (< 5) (at 1 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13846
R54252		 Darcie - Atenolol, 2004 Apgar score (first minute) < 4 late pregnancy prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.80 [0.08;39.94] C 2/40   0/14 2 40
ref
S13816
R54638		 Sibai - Labetalol, 1990 Apgar score<5 at 1minute 2nd and/or 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 1.20 [0.44;3.26] C 9/86   8/90 17 86
ref
Total 2 studies 1.25 [0.48;3.23] 19 126
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Darcie - Atenolol, 2004Darcie - Atenolol, 2004 1.80[0.08; 39.94]2409%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Sibai - Labetalol, 1990Sibai - Labetalol, 1990 1.20[0.44; 3.26]178691%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.25[0.48; 3.23]191260.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.80[0.08; 39.94]240 -NADarcie - Atenolol, 2004 1 case control studiescase control studies 0 RCTRCT 1.20[0.44; 3.26]1786 -NASibai - Labetalol, 1990 1 Type of controls unexposed, sickunexposed, sick 1.25[0.48; 3.23]191260%NADarcie - Atenolol, 2004 Sibai - Labetalol, 1990 2 Tags Adjustment   - No  - No 1.80[0.08; 39.94]240 -NADarcie - Atenolol, 2004 1   - Randomisation  - Randomisation 1.20[0.44; 3.26]1786 -NASibai - Labetalol, 1990 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.80[0.08; 39.94]240 -NADarcie - Atenolol, 2004 1   - Only chronic hypertension indication  - Only chronic hypertension indication 1.20[0.44; 3.26]1786 -NASibai - Labetalol, 1990 1 All studiesAll studies 1.25[0.48; 3.23]191260%NADarcie - Atenolol, 2004 Sibai - Labetalol, 1990 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.25[0.48; 3.23]191260%NADarcie - Atenolol, 2004 Sibai - Labetalol, 1990 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Firoz (Labetalol) (Apgar score <4 at 1 min (L ...Firoz (Labetalol) (Apgar score <4 at 1 min (Labetalol iv versus Nifedipine)) 2.13[0.22; 20.00]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Firoz (Atenolol) (Apgar score <4 at 1 min (ve ...Firoz (Atenolol) (Apgar score <4 at 1 min (versus Methyldopa)) 0.85[0.67; 1.08]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 metaPregmetaPreg 1.25[0.48; 3.23]0%126----Darcie - Atenolol, 2004 Sibai - Labetalol, 1990 20.510.01.0